

**27th Annual John Goldman Conference on
CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY**
October 10-12, 2025 – Estoril, Portugal

Chairs: J. Cortes, T.P. Hughes, D.S. Krause

Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, V. Helgason, S. T. Ong, J. Radich, D. Réa

Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann,
P. Laneuville, F-X. Mahon, D. Perrotti, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

Friday, October 10, 2025

08:00-08:05	Welcome	Jorge Cortes (Augusta)
08:05-08:10	Welcome to Estoril	António Almeida (Lisbon)*
08:10-08:20	iCMLf - A review	Jorge Cortes (Augusta)
SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2025 (12' + 3' discussion)		
Chairs: Daniele Sarnello (Glasgow)*, Kendra Sweet (Tampa)*		
08:20-08:35	Early response prediction by single-cell immune and signaling profiling in chronic myeloid leukemia	Stein-Erik Gullaksen (Bergen)
08:35-08:50	ENABLE: a phase 1 study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML	Fabian Lang (Frankfurt)
08:50-09:05	Next generation sequencing from dried blood spots in low- and middle-income countries: "spot on CML" results	Vivian Oehler (Seattle)
09:05-09:20	Tyrosine kinase inhibition alters macrophage polarization in chronic myeloid leukemia to regulate leukemic stem cell potential	Tiffany Ricketts (Birmingham, USA)
09:20-09:35	Asciminib shows superior tolerability vs Nilotinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from the phase 3b, randomized, open-label, ASC4START trial	François-Xavier Mahon (Bordeaux)
09:35-09:50	Detailed molecular insight into resistance mechanisms of the allosteric BCR::ABL1 inhibitor asciminib	Inga B. Leske (Marburg)
09:50-10:05	Mutually dependent leukaemia stem cell states govern lineage trajectories that reflect clinical outcomes in chronic phase CML	Mary Scott (Glasgow)

10:05-10:35 Coffee Break

TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE (1) (20' + 5' discussion)

Chair: Daniela Krause (Mainz)

10:35-10:55 Title TBA

Marieke Essers (Heidelberg)

10:55-11:00 Discussion

SCIENTIFIC SESSION 2: Stem Cells

Chair: Richard Van Etten (Irvine)*

11:00-11:15 **Keynote Presentation:**

Title TBA

David Vetrie (Glasgow)*

11:15-11:20 Discussion

Selected Abstracts: (12' + 3' discussion)

11:20 -11:35 Identification of leukemic stem cells of chronic myeloid leukemia in a new mouse model

Yasmine Pobiedonoscew (Bordeaux)

11:35-11:50 Exploring the role of megakaryocytes in leukemic stem cell persistence

Margherita Vieri (Aachen)

11:50-12:05 A potential role for IGFBP2 in regulating the CML stem cell niche

Henrike Jacobi (Aachen)

12:05-12:15 **JANET ROWLEY PRIZE PRESENTATION**

Presenter: Andreas Hochhaus (Jena)*

Awardee 2025: Satu Mustjoki (Helsinki)

JANET ROWLEY PRIZE: SPECIAL LECTURE (2)

Chair: Andreas Hochhaus (Jena)*

12:15-12:35 Title TBA

Satu Mustjoki (Helsinki)

12:35-12:40 Discussion

12:40-14:40 Lunch and Poster Viewing

13:30-14:30 SATELLITE SYMPOSIUM

**Balancing tolerability and efficacy in CML:
strategies to improve long-term outcomes in the newly diagnosed setting**

Chair: António Almeida (Lisbon)

Speakers: António Almeida (Lisbon), Jane F. Apperley (London), Tim Brümmendorf (Aachen)

This symposium is organized and sponsored by Novartis

SPECIAL LECTURE (3):

Chair: Mirle Schemionek (Aachen)*

14:40-15:00 Evolutionary therapy for metastatic cancer

Alexander Anderson (Tampa)

15:00-15:05 Discussion

SCIENTIFIC SESSION 3: Cell biology

Chair: Oliver Hantschel (Marburg)*

15:05-15:20 **Keynote Presentation:**

A single-cell chromatin accessibility atlas reveals transcription factor-driven epigenetic programmes underlying drug resistance and blast crisis progression in CML

Sin Tiong Ong (Singapore)*

15:20-15:25 *Discussion*

Selected Abstracts: (12' + 3' discussion)

15:25-15:40 A coordinated stress-adaptive response underlies the tumor suppressor role of GOS2 in CML

Briandy Fernandez-Marrero (El Paso)

15:40-15:55 Integrating genomic and transcriptomic features for predicting responses and outcomes in chronic myeloid leukemia on third-generation TKI therapy

Xiaoshuai Zhang (Beijing)

15:55-16:10 Complex metabolic reprogramming underlies TKI resistance in CML stem progenitor cells

Ilaria Stefania Pagani (Adelaide)

16:10-16:40 Coffee Break

MICHELE BACCARANI SPECIAL SYMPOSIUM (12' + 5' discussion)

Chair: Michael Deininger (Milwaukee)

16:40-16:50 Introduction

16:50-17:07 Title TBA

Gerlinde Wernig (Stanford)

17:07-17:24 Targeting Mutated Calreticulins in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Stefan Constantinescu (Brussels)

17:24-17:41 New developments in the treatment of Myelofibrosis, the future of Myeloproliferative disorders with focus on combinations

John Mascarenhas (New York)

17:41-17:58 Exploring new biomarkers in MPN

David Ross (Adelaide)

17:58-18:28 General Discussion

18:35-19:35 **Poster Session 1 and Welcome Get-Together**

Saturday, October 11, 2025

WORKSHOP FOR NON-CLINICAL SCIENTISTS #1: Mitochondria biology - Metabolism and other aspects of Mitochondria

Chairs: Vignir Helgason (Glasgow), Sin Tiong Ong (Singapore)

07:40-07:45 Introduction

07:45-08:10	Illuminating mitochondrial autophagy	Ian Ganley (Dundee)
08:10-08:20	<i>Discussion</i>	
08:20-08:45	Mitochondrial DNA mutations in cancer: prevalent and relevant - <i>EMBO Young Investigator Lecture</i> -	Payam Gammage (Glasgow)
08:45-08:55	<i>Discussion</i>	
08:55-09:20	Targeting mitochondrial metabolism to rescue Hematopoietic Stem Cell function	Els Mansell (Rotterdam)
09:20-09:30	<i>Discussion</i>	
09:30-09:40	Conclusion	

08:55-09:55 **CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**
 1. Pregnancy – Jane Apperley (London) and Ekaterina Chelysheva (Moscow)
 2. Dosing of the TKIs – Daniela Žáčková (Brno) and Mhairi Copland (Glasgow)

09:40-10:10 Coffee Break

SCIENTIFIC SESSION 4: Biomarkers, resistance and new targets

Chairs: Simona Soverini (Bologna)*

10:10-10:25 **Keynote Presentation:**

Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance

Susan Branford (Adelaide)*

10:25-10:30 *Discussion*

Selected Abstracts: (12' + 3' discussion)

10:30-10:45 Partner Matters: the role of the 5' ABL fusion gene in asciminib efficacy

Elias Lagonik (Adelaide)

10:45-11:00 STAT5-targeting monobodies as therapeutic (add-on) option in chronic myeloid leukemia

Inga B. Leske (Marburg)

11:00-11:15 DNA methylation instability as a biomarker for response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Dennis Kim (Toronto)

11:15-11:30 The majority of BCR::ABL1 mutations associated with clinical resistance to asciminib retain asciminib binding affinity, alter kinase structure, activate kinase activity and confer cross-resistance to TGRX-678

Ariel Leyte-Vidal (San Francisco)

11:30-11:45 Establishing an iPSC-based platform to elucidate and

John Joson Ng (Singapore)

overcome primary imatinib resistance in chronic myeloid leukaemia stem cells

11:45-13:40 Lunch and Poster Viewing

12:30-13:30 CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

1. Frontline therapy – Andreas Hochhaus (Jena) and Massimo Breccia (Rome)
2. MPN – David Ross (Adelaide) and John Mascarenhas (New York)
3. Meet the editor – Jorge Cortes (Augusta) and Robert P. Gale (London)

SPECIAL LECTURE (4):

Chair: Sin Tiong Ong (Singapore)*

13:40-14:00 ASXL1 mutation induces TKI resistance in CML cells through upregulation of ALOX5 expression Takeshi Kondo (Sapporo)

14:00-14:05 *Discussion*

SCIENTIFIC SESSION 5: New drugs and clinical trials

Chair: Fausto Castagnetti (Bologna)*

14:05-14:20 Keynote Presentation:

Targeting chronic myeloid leukemia with potent and specific BCR::ABL1 degraders

Michael Deininger (Milwaukee)*

14:20-14:25 *Discussion*

Selected Abstracts: (12' + 3' discussion)

14:25-14:40 Efficacy and safety of asciminib in patients with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial Jorge Cortes (Augusta)

14:40-14:55 Olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) Weiming Li (Wuhan)

14:55-15:10 First preliminary results of a multicenter randomized phase III study of vamorinib (PF-114) versus imatinib in Ph-positive chronic phase chronic myeloid leukemia patients Ekaterina Chelysheva (Moscow)

15:10-15:25 Asciminib Once or Twice Daily Demonstrates High Efficacy and Favorable Safety in Pretreated Patients with Chronic Myeloid Leukemia and Suboptimal Response, Resistance or Intolerance: 96-week Results from the ASC4OPT Study Carla Maria Boquimpani (Rio de Janeiro)

15:25-15:40 Interim analysis of a multicentre study of patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study) Nienke Lokhorst (Nijmegen)

15:40-16:10 *Coffee Break*

16:10-16:20 **JOHN GOLDMAN PRIZE PRESENTATION**

Presenter: François Guilhot (Poitiers)

Awardee 2025: Delphine Rea (Paris)

JOHN GOLDMAN PRIZE: SPECIAL LECTURE (5)

Chair: François Guilhot (Poitiers)

16:20-16:40 Title TBA

Delphine Rea (Paris)

16:40-16:45 *Discussion*

16:50-17:50 **Poster Session 2**

Sunday, October 12, 2025

07:00-08:00 John Goldman charity Fun Run, organized by the iCMLf (Pre-registration required)

WORKSHOP FOR NON-CLINICAL SCIENTISTS #2: Clonal tracking, lineage tracing, and fate mapping over time

Chairs: Ravi Bhatia (Birmingham, USA), Daniela Krause (Mainz)

09:00-09:05 Introduction

09:05-09:30 A track of the clones: new tools to study clonal evolution of blood stem cells

David Kent (York)

09:30-09:40 *Discussion*

09:40-10:05 Targeted readout of DNA methylation states in single cells enables joint profiling of clonal identity and cell state

Michael Scherer (Heidelberg)

10:05-10:15 *Discussion*

10:15-10:40 Family matters: clonal memory of cell division in blood progenitors

Alessandro Donada (Paris)

10:40-10:50 *Discussion*

10:50-11:00 Conclusion

SCIENTIFIC SESSION 6: CML special scenarios

Chair: Deborah White (Adelaide)*

09:10-09:25 **Keynote Presentation:**

The new ELN recommendations:
what is in, what is out, what is different, what is not

Dragana Milojkovic (London)*

09:25-09:30 *Discussion*

Selected Abstracts: (12' + 3' discussion)

09:30-09:45 Chronic Myeloid Leukemia (CML) Treatment Discontinuation After Two-Step Dose Reduction: First Results of the Phase 2 HALF Study

Daniela Žáčková (Brno)

09:45-10:00 Treatment-free remissions (TFR) in children with chronic myeloid leukemia (CML) -- Longer-term results from the Tata Memorial Hospital (TMH) pediatric CML(pCML) cohort Nirmalya Roy Moulik (Mumbai)

10:00-10:15 Dynamics and Outcomes of Second-Line Therapy in Pediatric Chronic Myeloid Leukemia: Insights from the Longitudinal German CML-paed II Cohort Stephanie Sembill (Erlangen)

10:15-10:30 Molecular response in pregnant chronic myeloid leukemia patients during interruptions of tyrosine kinase inhibitors therapy and impact of interferon on response preservation Ekaterina Chelysheva (Moscow)

10:30-11:00 Coffee Break

SPECIAL LECTURE (6):

Chair: Jerald Radich (Seattle)*

11:00-11:20 Advances in Natural Killer Cell (NK) Cancer Therapy Dan S. Kaufman (La Jolla)
11: 20-11:25 *Discussion*

ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY 2025

Chair: Hervé Dombret (Paris)*

11:25-11:30 Announcing the Awardee 2025 Hervé Dombret (Paris)*

11:30-11:40 Single-cell precision medicine: early profiling of therapy effects in clinical decision-making Stein-Erik Gullaksen (Bergen)

11:40-11:45 *Discussion*

11:45-11:55 iCMLf PRIZE PRESENTATION:

Presenter: Pier Paolo Piccaluga (Bologna)*

Awardee 2025: Nicholas A. Othieno-Abinya (Nairobi)

iCMLf PRIZE: SPECIAL LECTURE (7)

Chair: Pier Paolo Piccaluga (Bologna)*

11:55-12:15 Twenty years of managing chronic myeloid leukaemia in Kenya Nicholas A. Othieno-Abinya (Nairobi)

12:15-12:20 *Discussion*

12:20-12:25 Closing Remarks

MEETING CLOSURE